Quick answer: No source can support a Wolverine peptide dosing chart as of 2026-10-09. A chart is a set of claims about amounts, timing and route, and each claim needs a human study of a defined product behind it. For BPC-157 and TB-500 the published human record is a few small pilots, and no human trial of TB-500 was found. This page shows what a chart must cite and what circulating charts cite instead.
A chart looks like data. It has rows, columns and tidy units, and that format signals that someone measured something. This page asks the question a reader should ask of any chart: where did each cell come from? We print no chart of our own, because the sources we reviewed contain nothing to put in one.
What a dosing chart must cite
A dosing chart makes seven kinds of claim, and each one should trace to a document you can open. Here is the test applied to the claims a "Wolverine stack" chart usually makes. The stack itself has no fixed definition: sources describe it as two peptides, as four, or as BPC-157 alone, and one Australian government-funded men's health information site calls it "a marketing term, not a scientific one." Read more about that in the Wolverine stack guide.
| What a chart shows | What it would have to cite | What circulating charts cite instead |
|---|---|---|
| An amount per administration | A dose-ranging trial in people, using a defined product | A clinic page, a forum thread or an animal paper rescaled by the poster |
| How often and for how long | A trial that compared schedules and followed outcomes | Repetition of the same schedule across many pages |
| The route (injection, oral, nasal) | Human pharmacokinetic data for that route | Nothing; FDA's BPC-157 briefing found no human data for oral, subcutaneous, nasal or transdermal use |
| A ratio between the two peptides | A human study of the combination | Nothing in people; one 2026 rat study found the combination significant on one tendon score and no added benefit over TB-500 alone |
| Adjustments for weight, age or illness | Subgroup results and a regulator-reviewed label | Rules of thumb with no study cited |
| Warning signs and stop rules | Adverse-event data from controlled trials | Forum reports of "mild" effects; FDA says the risks of TB-500 in humans are unknown |
| The strength inside each vial | A batch analysis tied to the lot | The number printed on the vial label |
As of 2026-10-09. Sources are listed below; the FDA statements are from its BPC-157 and TB-500 briefing documents, on a meeting page current as of 2026-08-06.
The last row matters more than it looks. A chart that gives amounts per vial presumes the vial holds what it says. The question of what a label and a certificate of analysis do and do not prove has its own page: How to read a peptide label and COA.
Where circulating charts come from
We cannot trace any one chart to its author, and no source we read says who first posted one. What we can describe is the kinds of source that charts and "protocols" draw on, each attributed here and none endorsed.
- Clinic and shop pages. Pages that market the pair describe "protocols." One clinic page says "this protocol stacks four peptides" and adds that "legitimate variation" between clinics is normal. If variation is normal, there is no standard to chart.
- Peptide reference sites. One protocol-style reference page states that no study has tested the specific combination. The same page repeats an out-of-date FDA category label that FDA's own page no longer carries.
- Forum threads. The Reddit and forum claim types we mapped include swapping dosing and timing details. A health publisher's page describes reports of human use as "purely anecdotal." An Australian men's health information site says most information "comes from blog posts and user anecdotes." See the Reddit claims graded by evidence.
- Influencer posts. One newsletter post on a longer blend closes with the slogan "We ARE the human studies." A slogan is not a trial.
- Animal papers. Rat and mouse studies report what was given to animals. A chart that borrows those amounts is doing a conversion that none of the reviews we read endorses.
The result is a document that looks authoritative because many pages repeat it. Repetition is not replication. A figure copied across fifty pages is still one unsourced figure.
Why none passes
Take the strongest case, the published human evidence for BPC-157, and ask whether it could support a chart.
- A 2025 systematic review in HSS Journal included 36 studies, 35 preclinical and one clinical, and reported that no clinical safety data were found (PMID 40756949).
- A 2026 review in Pharmaceutics counted fewer than 30 subjects across three uncontrolled pilots and noted there is "no validated dosing regimen" (PMID 42198317).
- The three pilots are knee pain, interstitial cystitis, and an intravenous check in two participants. They were described as private-clinic work and had no placebo group. They were not designed to find an appropriate amount.
For TB-500, the FDA briefing says no articles were found in which TB-500 was given to humans and calls the safety risks "unknown." The full-length protein, thymosin beta 4, has human trials as eye drops, a skin gel and an intravenous product, but not for the fragment that FDA describes as TB-500 and not for tendon, muscle or joint injury. The comparison is laid out in the thymosin beta 4 and TB-500 sections of the dosage explanation.
A chart fails for four reasons, any one of which would be enough:
- No dose-finding evidence exists for either compound in people.
- No defined product exists, so a number has no fixed thing to attach to.
- No data for the combination exist in people.
- No regulator-reviewed label exists, and the label is where an amount, a route and a schedule are normally recorded.
FDA's compounding Q&A page (current as of 2025-09-16) says FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed. So even a product made by a pharmacy would not carry a regulator's endorsement of its strength.
What to ask a clinician instead
If you are considering any unapproved peptide, a licensed clinician is the right person to ask, and these questions make the conversation useful:
- What is known in people about this exact product and route?
- Who made it, and can the batch be tested?
- Is there an approved option with an established dose for the same problem?
- What would be monitored, and what would prompt stopping?
Related pages cover the tools that sit next to charts: the dosage calculator question, what a blend vial is, and what is known about capsules and oral forms. For the legal side, see BPC-157 and TB-500 for sale? What FDA status means. Back to the home page.
Sources
- FDA briefing document: BPC-157 read 2026-10-09
- FDA briefing document: TB-500 read 2026-10-09
- FDA: July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting page current as of 2026-08-06, read 2026-10-09
- FDA: Compounding and the FDA, questions and answers page current as of 2025-09-16, read 2026-10-09
- Vasireddi et al. 2025, HSS Journal PMID 40756949
- Mateescu et al. 2026, Pharmaceutics PMID 42198317
- Bicer et al. 2026, Joint Diseases and Related Surgery PMID 42542926
FAQ
Is there an official Wolverine peptide dosing chart?
No. No regulator, medical society or approved label publishes one. As of 2026-10-09 no FDA-approved drug contains BPC-157 or TB-500, so there is no label to base a chart on.
Why do the charts all look alike?
Pages copy from one another. Matching schedules across many sites show that the figures were repeated, not that they were tested. We found no trial behind them.
Could a chart be accurate even without a trial?
A chart could contain a figure that happens to be harmless or one that is not, and a reader cannot tell which. Without a study that measured outcomes, accuracy has no meaning to check against.
What about the amounts used in animal studies?
Animal papers report what was given to animals in that model. The reviews we read do not present a conversion to people, and we do not print animal amounts.
Does a clinic chart carry more weight than a forum chart?
A clinic page is a marketing claim from a business, and the clinic pages we read cite no trial for their figures. The FDA briefings are the more reliable guide to the evidence, and they report that human data are limited or absent.
Where can I check the current regulatory position?
FDA's bulk drug substances page and its advisory committee meeting page. As of 2026-10-09 we found no final FDA decision on listing either substance, so check those pages for updates.
Not medical advice. See the medical disclaimer.
